A recent CRISPR screen identified an essential role for FAS-FASL in antigen-specific T cell killing, and tumor-cell eradication by tumor-specific CTLs and CAR-T cells was abrogated in FAS-deficient target cells despite the presence of activated and functional CTLs in vitro and in vivo [11]. The gene discussed is FAS; the disease is neoplasm.